Genprex, INC. 8-K Filing
Ticker: GNPX · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1595248
Sentiment: neutral
Filing Stats: 1,316 words · 5 min read · ~4 pages · Grade level 14.8 · Accepted 2025-11-18 07:10:17
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251116_8k.htm (8-K) — 33KB
- 0001437749-25-035514.txt ( ) — 163KB
- gnpx-20251118.xsd (EX-101.SCH) — 3KB
- gnpx-20251118_def.xml (EX-101.DEF) — 11KB
- gnpx-20251118_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251118_pre.xml (EX-101.PRE) — 11KB
- gnpx20251116_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 18, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that the United States Patent and Trademark Office has granted Genprex a patent that covers the use of the Company's lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in combination with PD-L1 antibodies, such as Tecentriq, through 2037. The press release noted that in the Acclaim-3 clinical trial, the Company is combining REQORSA with Tecentriq, a PD-L1 antibody, and this patent secures exclusivity for this drug combination for the treatment of cancer, preventing would-be competitors from making, using or selling this drug combination. PD-L1 antibodies are a type of targeted immunotherapy that block the activity of PD-L1 immune checkpoint proteins present on the surface of cells. Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel. Should these applications grant, they would also be applicable to Genprex's Acclaim-3 clinical trial. Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech's Tecentriq (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as standard of care initial treatment. In this study, patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The Phase 2 expansion study follows the successful completion of the Phase 1 dose escalation portion of the study, which showed REQORSA was generally well tolerated. There were no dose limiting toxicities, and in Acclaim-3, the Phase 2 patients are receiving the same dose of REQORSA as patients in the Phase 2 portion of Acclaim-1. The Phase 2 expansion portion is exp
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 18, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)